For instance, looking into potential synergism between decitabine and Clec9A+-AFN, activity-on-target interferons inducing immune-driven antitumor effects by activating Clec9A+ dendritic cells in T-ALL [60] represents an interesting therapeutic strategy worthy of further investigation in the high-sensitivity subgroup for both T-LBL and T-ALL (Figure 4). This evidence concerns the gene CLEC9A and acute lymphoblastic leukemia.